5-methoxy-N,N- dimethyltryptamine - Biomind Labs
Alternative Names: 5-MeO-DMT-Biomind Labs; BMND-05; BMND-08Latest Information Update: 07 Mar 2024
Price :
$50 *
At a glance
- Originator Biomind Labs
- Class Analgesics; Anti-inflammatories; Antidementias; Antidepressants; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Ethers; Mood stabilisers; Small molecules; Tryptamines
- Mechanism of Action Serotonin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Alzheimer's disease
- Preclinical Pain
Most Recent Events
- 29 Feb 2024 Biomind Labs plans to seek Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) in Alzheimer’s Disease
- 29 Feb 2024 Pharmacokinetics, efficacy and adverse events data from a phase II trial in Alzheimer’s Disease released by Biomind Labs
- 29 Feb 2024 Biomind Labs plans a phase III trial in Alzheimer’s Disease